Role of tissue transglutaminase and effect of cantharidinate in human colorectal cancer

LAN-LAN YANG, CHONG-YANG LIANG, TIAN-CHENG LU, CHEN-YANG ZHI, BIN LIU, JIAN-HUA ZHOU, XU-MING LIU, HAI-CHENG GAO and WEI HUANG

Abstract. The role of tissue transglutaminase (tTG) in cancer development remains an important field of study. The aim of the current study was to understand the involvement of tTG in cancer and the inhibitory effect of cantharidinate on the expression of tTG in human colorectal cancer (CRC) using immunohistochemical and PCR analysis. The results showed that the expression of tTG increased in human CRC and cantharidinate inhibited the expression of tTG. These results suggested that tTG is significant in human CRC and that tTG may be an important target for tumor chemoprevention and treatment. Cantharidinate may be considered as a novel co-therapy for controlling tTG expression in human CRC.

Introduction

Human colorectal cancer (CRC) is a type of cancer that arises from uncontrolled cell growth in the colon or rectum, sections of the large intestine or in the appendix (1). Genetic analysis shows that colon and rectal tumors are essentially the same type of cancer (2). CRC is the third most commonly diagnosed type of cancer in males and the second in females, and in 2008 there was an estimated 1.2 million novel CRC cases and 608,700 mortalities (3,4). Symptoms of CRC typically include rectal bleeding and anemia, which may be associated with weight loss and changes in bowel habits (5). The majority of CRC cases are a result of lifestyle and increasing age, with a minority of cases associated with underlying genetic disorders (6,7). Cancers confined within the wall of the colon are often curable with surgery, while cancers that have metastasized around the body are usually incurable. At present, studies primarily focus on tumor chemotherapy (8); however, the pathogenesis of CRC remains unclear. Current management focuses on extending patient lifespan via chemotherapy and improving quality of life (9).

Tissue transglutaminase (tTG) is a matricellular protein, which is expressed in multiple tissue and cell types (10). It is unclear whether tTG is important in CRC and if so, whether tTG may be inhibited by certain drugs. Fluorouracil is a standard chemotherapeutic agent used in the treatment of CRC (11). Treatment options for CRC also include additional chemotherapeutic agents and targeted therapies, including cetuximab, panitumumab and bevacizumab (12). Correct use of these therapies may result in a positive impact on patient prognosis (13).

Previously, data concerning cancer treatment using traditional Chinese medicine has affected a number of cancer treatments (14). It remains unclear whether certain traditional Chinese medicines may be used to inhibit tTG expression and improve the symptoms of CRC. Cantharidin (also termed cantharidinate) has been used in traditional Chinese medicine (15,16). Cantharidinate induces cell cycle arrest and triggers apoptosis in various types of tumor cells, including hepatoma, myeloma, oral buccal carcinoma, leukemia, gastric cancer, human bladder carcinoma TSGH-8301, colorectal cancer colo 205, A549 human lung cancer and intestinal epithelial cells (17-20). Therefore, the present study investigated the involvement of tTG in human CRC and demonstrated that cantharidinate may be used to inhibit the expression of tTG.

Materials and methods

Patients and tissue specimens. Twenty human CRC tissue specimens were obtained from 12 males and 8 females,
(average age, 68.25 years; range, 21-87 years) by surgical resection between May 2011 and June 2012 in Jilin University Second Hospital (Jilin, China). Written informed patient consent was obtained and approval was acquired from the Jilin University Second Hospital Ethics Committee (no. 2012-43). Tissue microarrays (TMAs) were constructed. Histological tumor grade of colon and sigmoid colon tissue were included in the analysis. Expression of tTG was associated with patient demographics, adjuvant treatment regimens and histological parameters.

**Histopathologic examination.** Specimens and cells were examined using light microscopy (Eclipse TE-2000-U equipped with an attached SXMI2000F digital camera; Nikon, Tokyo, Japan) following haematoxylin and eosin (HE) staining.

**Immunohistochemical staining.** Paraffin-embedded slices (4-µm thick) were probed with anti-human tTG monoclonal antibody (Sigma-Aldrich, St. Louis, MO, USA; dilution, 1:300) at 4°C overnight. Sections were immersed in 0.3% H2O2 in absolute methanol for 15 min to block endogenous peroxidase. Color was developed using chromagen 3,3′-diaminobenzidine (DAB substrate kit and Immunohistochemistry kit; Biosynthesis Biotechnology, Beijing, China). Slices were counterstained with hematoxylin, mounted on glass coverslips and sealed with neutral resin.

**UCT-116 cell culture and treatment.** UCT-116 human CRC cell lines were donated from Jilin University Institute of Regenerative Medicine. UCT-116 cells were routinely cultured in Dulbecco's modified Eagle's media (DMEM; Gibco-BRL, Life Technologies, Carlsbad, CA, USA) supplemented with 20% fetal bovine serum (FBS; Gibco-BRL) and 50 U/ml antibiotics under the conditions of 5% CO2 at 37°C. Following trypsinization, cells were incubated in DMEM with 0.5% FBS for 24 h. Cells were treated with 2.5 µmol/L cantharidin, provided by Associate Professor Yang of the Second Hospital of Jilin University and 2.5 µmol/L fluorouracil (Shanghai Hanhong Group, Shanghai, China), with untreated cells used as a control, for 48 h.

**Quantitative PCR (qPCR) analysis of UCT-116 cells.** Total RNA was extracted using TRizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. First strand cDNA was synthesized using PrimeScript™RT enzyme mix I, oligo dT primers and random hexamers (Takara). qPCR analysis was performed using first strand cDNA, forward and reverse primers and the SYBR premix Ex Taq™ Green II kit (Takara Bio, Inc., Shiga, Japan). qPCR analysis was performed on a TMA, constructed from microarray samples was representative (Fig. 2A and B).

**Statistical analysis.** Statistical analysis of data was performed using SPSS Version 11 for Windows (SPSS, Inc., Chicago, IL, USA). All data are presented as the mean ± SEM. Statistical comparisons were determined by Student’s t-test and P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Clinicopathological features and patient outcome.** The present study was performed on a TMA, constructed from surgically resected samples of patients with varying grades of differentiation of CRC. The demographics of the patients are shown in Table I as well as the clinicopathological features of the colon and the grade of differentiation. The incidence of CRC of grades IIB, IIC, IIIB and IIIA in males was 8.3, 8.3, 8.3 and 0%, respectively. The incidence of CRC of grades IIB, IIC, IIIB and IIIA in females was 0, 0, 25 and 12.5%, respectively. The incidence of colon and sigmoid colon cancer was 75 and 25% in males and 40 and 60% in females, respectively.

**H&E of human CRC tissues.** Following standard H&E staining, normal colon tissue and the CRC TMAs were observed to have representative histological structures by microscopy (Fig. 1). The immunohistochemical staining of microarray samples was representative (Fig. 2A and B).

**Immunohistochemical staining of tTG in human CRC tissue.** Immunohistochemical staining was used to determine the expression of tTG protein in human CRC tissue. The results showed that tTG was expressed in the membrane and cytoplasm of the normal tissue of patients with CRC (Fig. 2A). The expression of tTG markedly increased in CRC tissue. tTG was primarily expressed in the tumor and interstitial regions (Fig. 2B). The expression of tTG exhibited a significant difference between CRC and normal tissue (P<0.01; Fig 2C).

<table>
<thead>
<tr>
<th>Grade of differentiation</th>
<th>Male (n=12)</th>
<th>Female (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIB</td>
<td>1 (8.3%)</td>
<td>0</td>
</tr>
<tr>
<td>IIC</td>
<td>1 (8.3%)</td>
<td>0</td>
</tr>
<tr>
<td>IIIB</td>
<td>1 (8.3%)</td>
<td>2 (25%)</td>
</tr>
<tr>
<td>IIIB</td>
<td>0</td>
<td>1 (12.5%)</td>
</tr>
<tr>
<td>A moderately differentiated adenocarcinoma</td>
<td>9 (75%)</td>
<td>5 (40%)</td>
</tr>
</tbody>
</table>

**Table I. Clinicopathological features of colon cancer patient cohort (n=20).**
H&E staining of UCT-116 cells. Pathological changes of UCT-116 human CRC cells in various groups are shown in Fig. 3A-C. The quantity of UCT-116 cells decreased 48 h following the application of fluorouracil and cantharidinate (Fig. 3B and C). This result suggested that cantharidinate may exert an accessorical effect and may reduce the chemotherapeutic time, subsequently decreasing the side-effects of the treatment of human CRC.

Immunohistochemical staining detects tTG in UCT-116 cells. Fig. 4 shows tTG immunohistochemical staining in UCT-116 cells. Immunohistochemical staining detected a high level of tTG in the untreated UCT-116 cell control (Fig. 4A and D). Cantharidinate and fluorouracil treatment decreased the level of tTG in UCT-116 cells significantly (P<0.05; Fig. 4B-D). This result suggested that cantharidinate may inhibit the expression of tTG and block tumor growth.

PCR analysis results. To determine whether the tTG mRNA level in UCT-116 cells altered following the application of cantharidinate, qPCR analysis was performed. In Fig. 5, the expression of tTG mRNA in the cantharidinate group decreased to 0.69-fold that of the untreated cancer cell control (P<0.05). The level of tTG in the cantharidinate group was
approximately the same as that in the fluorouracil group. This result suggested that cantharidinate may kill tumor cells by inhibiting tTG mRNA expression.

Discussion

tTGs are a family of structurally and functionally related proteins, which are widely distributed in all living organisms (10). There has been an increase in studies supporting the hypothesis that dysregulated expression and function of tTG contributes to pathological conditions, including cancer metastasis, tissue fibrosis, celiac disease, neurodegenerative disorders and diseases associated with the defective assembly of the stratum corneum of the skin (10). However, it remains unclear whether tTG is significant in CRC.

The present study demonstrated that levels of tTG were increased in the process of tumor occurrence and progression. The roles of tTG upregulation in cancers may involve the following. Agnihotri et al observed that tTG upregulation is associated with the activation of nuclear transcription factor-κB (NF-κB), Akt, focal adhesion kinase and hypoxia-inducible factor, thus tTG may serve as a central mediator with a key role in the inflammation-induced progression of mammary epithelial cancer cells (21). Yakubov et al reported that extracellular tTG promotes the metastasis of ovarian cancer by noncanonical NF-κB activation (22). Furthermore, Caffarel et al demonstrated that tTG is able to promote the progression of cervical squamous cell carcinoma by enhancing the pro-malignant effects of oncostatin M receptor overexpression (23). Wang et al suggested that extracellular tTG has a crucial role in matrix-bound VEGF-mediated angiogenesis (24).

A desirable property of an anticancer drug is to induce the death of tumor cells with few side effects on normal cells (12,13,15,16). The present study demonstrated that cantharidinate induced an inhibitory effect on tTG, which is involved in human CRC. The effects of cantharidinate are similar to that of fluorouracil. Cantharidinate inhibits the proliferation of human CRC cells with an IC₅₀ of 2.5 µM and cantharidinate has marginal cytotoxicity in normal cells (data not shown). The present study demonstrated that cantharidinate reduced the expression of mRNA and protein levels of tTG in
human CRC cells. To the best of our knowledge (15-20), the current study is the first to show that the expression of tTG mRNA and protein are downregulated by cantharidinate.

In conclusion, cantharidinate is significant in human CRC as it inhibits the expression of tTG. Therefore, cantharidinate may be considered to be a novel additional drug for controlling the expression of tTG in human CRC and the growth of human CRC.

References